Genmab — Juli 2020
-
Novartis also with a new trial , for patients that want to switch to Ofa from another CD20 https://www.clinicaltrials.gov/ct2/show/NCT04486716?term=NCT04486716&draw=2&rank=1
-
Lidt mere om Lazertinib https://www.fiercebiotech.com/biotech/janssen-taps-south-korea-s-yuhan-for-tagrisso-rival Gode data og baren er sat højt.
-
De stoffer I nævner Amivantamab, Lazertinib..Hvem har de forbindelse til ? Kan ikke finde ud af om det er godt eller skidt for genmab.
-
God morgen.
-
Nogen der husker strukturen på en lignende aftale. Den er selvfølgelig backloaded i høj grad, men må også være ret simpel, da man jo for mange af programmerne ikke kendte targets og dermed mulige indikationer. Så mon den alene går på første indikation der kommer hele vejen, for de milestones det gælder klinisk udvikling og registrering. Gætter på at mindst halvdelen af milestonepakken er salgsmilestones
-
from 2019 : Janssen DuoBody Collaboration
In July 2012, we entered into a collaboration with Janssen to create and develop bispecific antibodies using our DuoBody platform. Under this agreement, Janssen received an exclusive worldwide license to use the DuoBody technology to create panels of bispecific antibodies (up to 10 DuoBody programs) to multiple disease target combinations. We recorded an upfront payment of $3.5 million from Janssen and will potentially be entitled to milestone and -
and license payments of up to approximately $175.0 million, as well as royalties for each commercialized DuoBody product. Janssen may terminate this agreement in whole or with respect to any particular target binding pair upon providing 120 days' prior written notice to us in accordance with the terms of the agreement.
-
Under the terms of a December 2013 amendment, Janssen was entitled to work on up to 10 additional programs. In exchange, we recorded an initial payment of $2.0 million from Janssen and are potentially entitled to receive average milestone and license payments of approximately $191.0 million if Janssen successfully initiates, develops and commercializes all such additional programs. In addition, we will be entitled to royalties on net sales of any commercialized products.
-
As of March 31, 2019, Janssen has exercised 14 licenses under this collaboration and we have recorded $60.0 million in milestone payments to date. No further options remain for potential use by Janssen. Six product candidates are currently in clinical development by Janssen under this agreement.
-
Do we know if this amivantamab/lazertinib kombo is targetting first line lung cancer patients?
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind